Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report) has been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $12.3250.
HLN has been the topic of a number of research reports. Wall Street Zen lowered Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. Finally, The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 10th.
Get Our Latest Stock Analysis on Haleon
Hedge Funds Weigh In On Haleon
Haleon Trading Up 1.3%
HLN opened at $9.43 on Friday. The stock has a market capitalization of $41.99 billion, a P/E ratio of 24.18, a P/E/G ratio of 2.80 and a beta of 0.20. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. Haleon has a 12 month low of $8.71 and a 12 month high of $11.42. The firm’s fifty day simple moving average is $9.29 and its 200 day simple moving average is $9.93.
Haleon Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Articles
- Five stocks we like better than Haleon
- Investing in Construction Stocks
- CAVA Stock Looking for Direction After Earnings Miss
- How to Short Nasdaq: An Easy-to-Follow Guide
- 3 Small AI Stocks Ready to Explode (All Under $20)
- Why is the Ex-Dividend Date Significant to Investors?
- After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
